Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer

Taeko Matsuoka, Koji Kawai, Tomokazu Kimura, Takahiro Kojima, Mizuki Onozawa, Jun Miyazaki, Hiroyuki Nishiyama, Shiro Hinotsu, Hideyuki Akaza

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Methods: A total of 3,752 patients with stage IV disease from the prospective nationwide cohort database of the Japan Study Group of Prostate Cancer (J-CaP) were enrolled. All patients started primary androgen deprivation therapy (PADT) between 2001 and 2003, and the present study was performed using the data set from December 2011. Patients were divided into two groups according to initial treatments: CAB with luteinizing hormone-releasing hormone agonist (LHRH) plus anti-androgen (AA) and non-CAB treatments such as LHRH monotherapy. The overall survival (OS) and cancer-specific survival (CSS) for each group were estimated by the Kaplan–Meier method.

Purpose: To clarify which subset of stage IV prostate cancer patients benefit from combined androgen blockade (CAB) using Japanese nationwide database.

Results: A total of 2,967 patients (79.1 %) received CAB. Overall, no significant difference was observed in OS and CSS between the CAB group and the non-CAB group. However, CAB resulted in significantly better OS and CSS compared to non-CAB in patients with very high Japan Cancer of the Prostate Risk Assessment (J-CAPRA) scores of ten or greater (P = 0.007 and 0.013, respectively). Multivariate analysis revealed that CAB was an independent predictive factor for better OS (P = 0.013, hazard ratio = 0.83).

Conclusions: Based on large-scale nationwide database, as PADT for prostate cancer patients with very high-risk disease, CAB resulted in better OS than other endocrine treatments.

Original languageEnglish
Pages (from-to)759-765
Number of pages7
JournalJournal of Cancer Research and Clinical Oncology
Volume141
Issue number4
DOIs
Publication statusPublished - 2015

Fingerprint

Androgens
Prostatic Neoplasms
Survival
Therapeutics
Databases
Gonadotropin-Releasing Hormone
Japan
Neoplasms
Multivariate Analysis

Keywords

  • Combined androgen blockade
  • Primary androgen deprivation therapy
  • Prostate cancer
  • Stage IV

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Matsuoka, T., Kawai, K., Kimura, T., Kojima, T., Onozawa, M., Miyazaki, J., ... Akaza, H. (2015). Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer. Journal of Cancer Research and Clinical Oncology, 141(4), 759-765. https://doi.org/10.1007/s00432-014-1856-3

Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer. / Matsuoka, Taeko; Kawai, Koji; Kimura, Tomokazu; Kojima, Takahiro; Onozawa, Mizuki; Miyazaki, Jun; Nishiyama, Hiroyuki; Hinotsu, Shiro; Akaza, Hideyuki.

In: Journal of Cancer Research and Clinical Oncology, Vol. 141, No. 4, 2015, p. 759-765.

Research output: Contribution to journalArticle

Matsuoka, T, Kawai, K, Kimura, T, Kojima, T, Onozawa, M, Miyazaki, J, Nishiyama, H, Hinotsu, S & Akaza, H 2015, 'Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer', Journal of Cancer Research and Clinical Oncology, vol. 141, no. 4, pp. 759-765. https://doi.org/10.1007/s00432-014-1856-3
Matsuoka, Taeko ; Kawai, Koji ; Kimura, Tomokazu ; Kojima, Takahiro ; Onozawa, Mizuki ; Miyazaki, Jun ; Nishiyama, Hiroyuki ; Hinotsu, Shiro ; Akaza, Hideyuki. / Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer. In: Journal of Cancer Research and Clinical Oncology. 2015 ; Vol. 141, No. 4. pp. 759-765.
@article{6e3ee7eda9ac43979fdaa4f3aa6a6532,
title = "Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer",
abstract = "Methods: A total of 3,752 patients with stage IV disease from the prospective nationwide cohort database of the Japan Study Group of Prostate Cancer (J-CaP) were enrolled. All patients started primary androgen deprivation therapy (PADT) between 2001 and 2003, and the present study was performed using the data set from December 2011. Patients were divided into two groups according to initial treatments: CAB with luteinizing hormone-releasing hormone agonist (LHRH) plus anti-androgen (AA) and non-CAB treatments such as LHRH monotherapy. The overall survival (OS) and cancer-specific survival (CSS) for each group were estimated by the Kaplan–Meier method.Purpose: To clarify which subset of stage IV prostate cancer patients benefit from combined androgen blockade (CAB) using Japanese nationwide database.Results: A total of 2,967 patients (79.1 {\%}) received CAB. Overall, no significant difference was observed in OS and CSS between the CAB group and the non-CAB group. However, CAB resulted in significantly better OS and CSS compared to non-CAB in patients with very high Japan Cancer of the Prostate Risk Assessment (J-CAPRA) scores of ten or greater (P = 0.007 and 0.013, respectively). Multivariate analysis revealed that CAB was an independent predictive factor for better OS (P = 0.013, hazard ratio = 0.83).Conclusions: Based on large-scale nationwide database, as PADT for prostate cancer patients with very high-risk disease, CAB resulted in better OS than other endocrine treatments.",
keywords = "Combined androgen blockade, Primary androgen deprivation therapy, Prostate cancer, Stage IV",
author = "Taeko Matsuoka and Koji Kawai and Tomokazu Kimura and Takahiro Kojima and Mizuki Onozawa and Jun Miyazaki and Hiroyuki Nishiyama and Shiro Hinotsu and Hideyuki Akaza",
year = "2015",
doi = "10.1007/s00432-014-1856-3",
language = "English",
volume = "141",
pages = "759--765",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer

AU - Matsuoka, Taeko

AU - Kawai, Koji

AU - Kimura, Tomokazu

AU - Kojima, Takahiro

AU - Onozawa, Mizuki

AU - Miyazaki, Jun

AU - Nishiyama, Hiroyuki

AU - Hinotsu, Shiro

AU - Akaza, Hideyuki

PY - 2015

Y1 - 2015

N2 - Methods: A total of 3,752 patients with stage IV disease from the prospective nationwide cohort database of the Japan Study Group of Prostate Cancer (J-CaP) were enrolled. All patients started primary androgen deprivation therapy (PADT) between 2001 and 2003, and the present study was performed using the data set from December 2011. Patients were divided into two groups according to initial treatments: CAB with luteinizing hormone-releasing hormone agonist (LHRH) plus anti-androgen (AA) and non-CAB treatments such as LHRH monotherapy. The overall survival (OS) and cancer-specific survival (CSS) for each group were estimated by the Kaplan–Meier method.Purpose: To clarify which subset of stage IV prostate cancer patients benefit from combined androgen blockade (CAB) using Japanese nationwide database.Results: A total of 2,967 patients (79.1 %) received CAB. Overall, no significant difference was observed in OS and CSS between the CAB group and the non-CAB group. However, CAB resulted in significantly better OS and CSS compared to non-CAB in patients with very high Japan Cancer of the Prostate Risk Assessment (J-CAPRA) scores of ten or greater (P = 0.007 and 0.013, respectively). Multivariate analysis revealed that CAB was an independent predictive factor for better OS (P = 0.013, hazard ratio = 0.83).Conclusions: Based on large-scale nationwide database, as PADT for prostate cancer patients with very high-risk disease, CAB resulted in better OS than other endocrine treatments.

AB - Methods: A total of 3,752 patients with stage IV disease from the prospective nationwide cohort database of the Japan Study Group of Prostate Cancer (J-CaP) were enrolled. All patients started primary androgen deprivation therapy (PADT) between 2001 and 2003, and the present study was performed using the data set from December 2011. Patients were divided into two groups according to initial treatments: CAB with luteinizing hormone-releasing hormone agonist (LHRH) plus anti-androgen (AA) and non-CAB treatments such as LHRH monotherapy. The overall survival (OS) and cancer-specific survival (CSS) for each group were estimated by the Kaplan–Meier method.Purpose: To clarify which subset of stage IV prostate cancer patients benefit from combined androgen blockade (CAB) using Japanese nationwide database.Results: A total of 2,967 patients (79.1 %) received CAB. Overall, no significant difference was observed in OS and CSS between the CAB group and the non-CAB group. However, CAB resulted in significantly better OS and CSS compared to non-CAB in patients with very high Japan Cancer of the Prostate Risk Assessment (J-CAPRA) scores of ten or greater (P = 0.007 and 0.013, respectively). Multivariate analysis revealed that CAB was an independent predictive factor for better OS (P = 0.013, hazard ratio = 0.83).Conclusions: Based on large-scale nationwide database, as PADT for prostate cancer patients with very high-risk disease, CAB resulted in better OS than other endocrine treatments.

KW - Combined androgen blockade

KW - Primary androgen deprivation therapy

KW - Prostate cancer

KW - Stage IV

UR - http://www.scopus.com/inward/record.url?scp=84925463203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925463203&partnerID=8YFLogxK

U2 - 10.1007/s00432-014-1856-3

DO - 10.1007/s00432-014-1856-3

M3 - Article

C2 - 25326347

AN - SCOPUS:84925463203

VL - 141

SP - 759

EP - 765

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 4

ER -